The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2022 | Preventing ibrutinib flare in CLL
In this video, Paul Hampel, MD, Mayo Clinic, Rochester, MN, discusses ibrutinib flare in chronic lymphocytic leukemia (CLL) and methods to prevent this. Dr Hampel first explains how ibrutinib flare occurs, and further emphasizes the importance of better identifying patients at risk for disease flare. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
